Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Superconductor Corporation (AMSC) vs Bristol-Myers Squibb Co (BMY) Price & Performance

American Superconductor CorporationTrade
Bristol-Myers Squibb CoTrade

Price performance (Past 24H)

Key statistics

American Superconductor Corporation vs Bristol-Myers Squibb Co — how do they compare? American Superconductor Corporation trades at $32.44 (market cap $1.56B), while Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 83.3× American Superconductor Corporation's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.

AMSCBMY
Market Cap
$1.56B$129.94B
Sector
TechnologyHealth
52-Week High
$66.68$65.89
52-Week Low
$25.95$42.60
Enterprise Value
$1.42B$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Superconductor Corporation

AMSC trades at $32.28, up 4.16% today, but faces a bearish technical outlook with 14 sell signals versus 3 buys. The company reported strong revenue growth with Q1 2026 sales up 30% to $94.1M (Zacks, Aug 7, 2026) and a record backlog over $400M, though Q2 earnings missed estimates amid margin pressure. Net income margin improved dramatically to 42.56% in 2026 from 2.7% in 2025, but cash flow turned negative with a $60M net outflow in 2026.

The stock presents a mixed opportunity: robust order growth and expanding margins support upside, but high EV/EBITDA (65.73) and technical weakness pose risks. Analyst consensus is bullish (53% Buy), yet investors should watch execution on backlog conversion and margin sustainability amid competitive and cost pressures.

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Superconductor Corporation

AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.

Read more on AMSC

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY